In contrast to the traditional methodology for developing small molecule inhibitors, we employed a protein degradation-targeting therapeutic strategy and developed a potent Cdc20 degrader to destroy Cdc20 in triple negative breast cancer cells, which provides a potential valuable approach to treat breast cancer. Here, CDC20 is linked to breast carcinoma.